Description: This product is a fixed-dose combination tablet containing low-dose aspirin and vonoprazan fumarate. It is designed to be a single medication for patients who need the antiplatelet effects of aspirin but are also at a high risk of developing gastric or duodenal ulcers, a common side effect of long-term aspirin use. Vonoprazan’s inclusion aims to improve patient adherence by reducing the need for two separate prescriptions and to effectively prevent the recurrence of ulcers.

Indication: This drug is indicated for the prevention of thrombosis and embolism in patients with a history of or who are at risk for conditions such as:

• Angina pectoris
• Myocardial infarction (heart attack)
• Ischemic cerebrovascular disease (e.g., transient ischemic attack, cerebral infarction)

It is also used to prevent thrombosis/embolism after coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). A crucial aspect of its indication is its use in patients who have a history of peptic ulcers and require long-term low-dose aspirin therapy.

Mechanism of Action: The product’s effect is due to the combined action of its two active ingredients:

• Aspirin: Aspirin is a non-steroidal anti-inflammatory drug (NSAID) that works as an antiplatelet agent. Its mechanism involves the irreversible inhibition of the enzyme cyclooxygenase-1 (COX-1) in platelets. By blocking COX-1, aspirin prevents the formation of thromboxane A2 (

TXA2​

), a powerful molecule that causes platelets to clump together and form blood clots. This action suppresses platelet aggregation and helps to prevent blood clots from forming.

• Vonoprazan: Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB). It works by reversibly and competitively binding to the potassium (

K+

) binding site of the

H+,K+

-ATPase (the “proton pump”) in the stomach’s parietal cells. This action effectively blocks gastric acid secretion, regardless of whether the pump is actively secreting acid. Unlike proton pump inhibitors (PPIs), Vonoprazan does not require an acidic environment to become active, allowing for a faster and more potent acid-suppressing effect. Its role in this combination product is to counteract the ulcer-causing effects of aspirin by significantly reducing stomach acid production.